Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2013 Oct;13(10):685-700. doi: 10.1038/nrc3580.

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Author information

1
Department of Molecular Biology, Building 6L, Umeå University, Umeå S-90187, Sweden.

Erratum in

  • Nat Rev Cancer. 2013 Nov;13(11):820.

Abstract

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.

PMID:
24060861
DOI:
10.1038/nrc3580
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center